| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1504 | |
| Phytochemical name or plant extracts | Panaxadiol | |
| PMID | 33345701 | |
| Literature evidence | was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. 2730. | |
| IUPAC name | (3S,5R,8R,9R,10R,12R,13R,14R,17S)-4,4,8,10,14-pentamethyl-17-[(2R)-2,6,6-trimethyloxan-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,12-diol | |
| Phytochemicals’ class or type of plant extracts | Triterpenoid saponin | |
| Source of phytochemicals or plant Extracts | Panax ginseng | |
| Geographical availability | Khabarovsk, Korea, Manchuria, Primorye | |
| Plant parts | NA | |
| Other cancers | Breast cancer, Colorectal cancer, Colon cancer, Lung cancer | |
| Target gene or protein | MMP9, CDK2, CDK4, p21, p27, Cyclin D1, CDK6, EGFR,HER2 | |
| Gene or Protein evidence | PD down-regulated the expression of Cyclin D1, cdk2, cdk4, cdk6, P-p38, and MMP9, and up-regulated p21 and p27. This study reveals that Panaxadiol hit molecule can be developed as a novel multi-target EGFR and HER2 target inhibitor with greater potential and low toxicity. | |
| Target pathways | PD regulated the protein expression of P-p38 and MMP9 in MAPK pathway. | |
| IC50 | NA | |
| Potency | Hydrogen bond analysis revealed Panaxadiol being a good inhibitor of EGFR and HER2. | |
| Cell line/ mice model | MCF-7, A549 | |
| Additional information | Panaxadiol derivatives 3, 12, and 13 showed significant inhibition of cellular proliferation against cancer cells compared with PD, panaxadiol derivative 13 showed the strongest inhibitory effect, which significantly increased the cytotoxicity of PD and was stronger than the positive control (mitomycin) | |
| PubChem ID | 73498 | |
| Additional PMIDs | 31725193 34619469 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:91472-1 | |
| Safety | NA |